PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma-Reference-Cited by-同舟云学术

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

Published:2017-06-08 Issue:23 Volume:129 Page:3071-3073
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Nayak Lakshmi¹²,Iwamoto Fabio M.³,LaCasce Ann¹²,Mukundan Srinivasan¹²,Roemer Margaretha G. M.¹,Chapuy Bjoern¹,Armand Philippe¹²,Rodig Scott J.¹²,Shipp Margaret A.¹²

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA;

2. Brigham and Women’s Hospital, Boston, MA; and

3. New York Presbyterian Hospital, New York, NY

Abstract

Key Points Genetic analysis reveals frequent 9p24.1/PD-L1/PD-L2 copy-number alterations and increased expression of the PD-1 ligands in PCNSL and PTL. PD-1 blockade with nivolumab demonstrated activity in patients with relapsed/refractory PCNSL and PTL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/23/3071/1400799/blood764209.pdf

Reference23 articles.

1. Diagnosis and treatment of primary CNS lymphoma;Korfel;Nat Rev Neurol,2013

2. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology;Hoang-Xuan;Lancet Oncol,2015

3. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network;Langner-Lemercier;Neuro-oncol,2016

4. Targetable genetic features of primary testicular and primary central nervous system lymphomas;Chapuy;Blood,2016

5. Primary testicular lymphoma;Cheah;Blood,2014

Cited by 368 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy;Current Medicinal Chemistry;2024-10

2. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study;Signal Transduction and Targeted Therapy;2024-09-04

3. Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature;Leukemia & Lymphoma;2024-09-03

4. ACT001 inhibits primary central nervous system lymphoma tumor growth by enhancing the anti-tumor effect of T cells;Biomedicine & Pharmacotherapy;2024-09

5. Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study;BMC Medical Imaging;2024-08-26